ExecEdge

Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication

Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication

By Thomas S. Green Apollomics Inc. (Nasdaq: APLM) said it saw strong results from two clinical trials for Vebreltinib, designed to target non-small cell lung...

Duckhorn Portfolio 1Q Net Income at High End of Expectations

Duckhorn Portfolio 1Q Net Income at High End of Expectations

Vince Holding 3Q Profit Climbs on Cost Savings Program

Vince Holding 3Q Profit Climbs on Cost Savings Program

Octave Bioscience Announces New CEO, Board Chairman

Tims China First Quarter Revenue Surges 50%

Tims China First Quarter Revenue Surges 50%

Direct Digital Holdings Surges 50% After Raising Guidance

Direct Digital Holdings Surges 50% After Raising Guidance

AvePoint Second Quarter Revenue Jumps 16%; Raises Full Year Guidance

Bowlero Initiated with “Buy” Rating and $16 Price Target at Oppenheimer

Bowlero Initiated with “Buy” Rating and $16 Price Target at Oppenheimer

Sustainable CPG Grove Collaborative Raises FY 2022 Guidance

Sustainable CPG Grove Collaborative Raises FY 2022 Guidance

F45 Posts 8% Rise in Third Quarter Sales, Reaffirms Full Year Guidance

F45 Posts 8% Rise in Third Quarter Sales, Reaffirms Full Year Guidance

On Reports 78% rise in First Quarter Sales, Hits New Record

On Reports 78% rise in First Quarter Sales, Hits New Record

Input your search keywords and press Enter.